» Articles » PMID: 30279248

Olmesartan-induced Enteropathy

Overview
Journal BMJ Case Rep
Specialty General Medicine
Date 2018 Oct 4
PMID 30279248
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Olmesartan-induced enteropathy (OIE) typically presents with a constellation of signs and symptoms including chronic diarrhoea, weight loss and villous atrophy on biopsy. We describe a 68-year-old Caucasian woman with a history of hypothyroidism and hypertension who presented to our hospital with recurrent episodes of acute intermittent diarrhoea, nausea, vomiting, renal failure and 15 lbs weight loss. After an extensive workup, she was diagnosed with possible OIE. Cessation of the offending drug resulted in improvement of clinical symptoms and also hospital admissions for severe diarrhoea reinforcing the diagnosis of OIE. Among the adverse effects of drug therapy, diarrhoea is a relatively frequent adverse event accounting for about 7%. This report serves as an addition to existing literature and to increase the awareness of olmesartan-induced sprue-like enteropathy among the primary care physicians and gastroenterologists.

Citing Articles

Olmesartan-Induced Enteropathy: A Rare Case of Chronic Diarrhea.

Gurgel S, Medeiros K, Lima de Paiva S, Gurgel Filho J Case Rep Med. 2024; 2024:2666671.

PMID: 39735218 PMC: 11671654. DOI: 10.1155/carm/2666671.


Olmesartan-Induced Enteropathy: A Report of an Unusual Cause of Chronic Diarrhea.

Sotiropoulos C, Sakka E, Diamantopoulou G, Theocharis G, Thomopoulos K Cureus. 2021; 13(8):e17004.

PMID: 34540405 PMC: 8423377. DOI: 10.7759/cureus.17004.


Effects of Drugs and Excipients on Hydration Status.

Puga A, Lopez-Oliva S, Trives C, Partearroyo T, Varela-Moreiras G Nutrients. 2019; 11(3).

PMID: 30897748 PMC: 6470661. DOI: 10.3390/nu11030669.


Significant Weight Loss in a Patient Taking Olmesartan: An Unusual Case Report.

Makri A, Florentin M, Elisaf M, Liamis G Curr Drug Saf. 2019; 14(3):238-241.

PMID: 30848210 PMC: 6865051. DOI: 10.2174/1574886314666190307142111.

References
1.
Menne J, Haller H . Olmesartan and intestinal adverse effects in the ROADMAP study. Mayo Clin Proc. 2012; 87(12):1230-1. PMC: 3547579. DOI: 10.1016/j.mayocp.2012.10.005. View

2.
Rubio-Tapia A, Herman M, Ludvigsson J, Kelly D, Mangan T, Wu T . Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc. 2012; 87(8):732-8. PMC: 3538487. DOI: 10.1016/j.mayocp.2012.06.003. View

3.
Degaetani M, Tennyson C, Lebwohl B, Lewis S, Abu Daya H, Arguelles-Grande C . Villous atrophy and negative celiac serology: a diagnostic and therapeutic dilemma. Am J Gastroenterol. 2013; 108(5):647-53. DOI: 10.1038/ajg.2013.45. View

4.
Ziegler T, Fernandez-Estivariz C, Gu L, Fried M, Leader L . Severe villus atrophy and chronic malabsorption induced by azathioprine. Gastroenterology. 2003; 124(7):1950-7. DOI: 10.1016/s0016-5085(03)00405-0. View

5.
Matt P, Schoenhoff F, Habashi J, Holm T, van Erp C, Loch D . Circulating transforming growth factor-beta in Marfan syndrome. Circulation. 2009; 120(6):526-32. PMC: 2779568. DOI: 10.1161/CIRCULATIONAHA.108.841981. View